GlassScriptPhysician profile
Bria A Mckee
NPI 1679946206
$48,132.07
in general payments reported to CMS, 2019-2025
38 companies · $910 in 2025
The $910 reported for 2025 was more than what 85% of Family Health providers received nationally (typical 2025 total: $209).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20K · 2022: $21K · 2023: $4,996 · 2024: $1,488 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,789 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,788.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,605.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $42,488.55 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $1,456.95 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $858.36 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Insulet Corporation | $466.09 | 2022-2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $439.12 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $363.21 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $304.33 | 2021-2025 | Farxiga, Airsupra, Tezspire |
| Medtronic, INC. | $236.48 | 2022 | |
| Abbvie INC. | $223.74 | 2023-2025 | |
| Amgen INC. | $126.43 | 2021-2023 | Tezspire, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $122.90 | 2021-2025 | |
| Dexcom, INC. | $102.07 | 2023-2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $93.21 | 2024 | |
| Esperion Therapeutics, INC. | $84.77 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.71 | 2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bria Mckee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.